U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07822399) titled 'A Study of MGC030 in Participants With Advanced Solid Tumors' on Sept. 10.
Brief Summary: The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of MGC030. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors of select types.
The main question the study aims to answer is:
* What types of side effects will participants experience when receiving MGC030?
* Can MGC030 cause cancer to shrink, remain stable, or able to control disease progression of participants with advanced solid tumors? Participants will
*...